<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02497248</url>
  </required_header>
  <id_info>
    <org_study_id>PERSONALIZE-AF</org_study_id>
    <nct_id>NCT02497248</nct_id>
  </id_info>
  <brief_title>Non-invasive Characterization of the Mechanisms of Atrial Fibrillation Maintenance</brief_title>
  <acronym>PERSONALIZE</acronym>
  <official_title>PERSONALIZE-AF: Non-invasive Characterization of the Mechanisms of Atrial Fibrillation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospital General Universitario Gregorio Marañon</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Universitat Politècnica de València</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Instituto de Salud Carlos III</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Hospital General Universitario Gregorio Marañon</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Currently available antiarrhythmic drugs for the treatment of atrial fibrillation (AF) have a
      limited efficacy and often cause long-term side effects. Pulmonary vein isolation is the
      therapy of choice in drug-refractory patients. Recent studies have shown that ablation have a
      greater efficacy in patients in whom AF is maintained hierarchically and after ablation of
      rotors. The non-invasive identification of specific mechanism of AF maintenance in each
      patient could allow the selection of the most appropriate treatment.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The MAIN GOAL of this project is to clinically validate the technology for the noninvasive
      identification of the mechanisms responsible for maintenance of AF by body surface electrical
      mapping. To achieve this goal, noninvasive mapping of the atrial activity will be correlated
      with simultaneous endocardial mapping (high density contact catheters) using advanced signal
      analyses techniques (Dominant frequency, phase and causality mapping, inverse solution
      problem). These analyses will be performed in patients with different mechanisms of
      maintenance of AF (e.g. paroxysmal, persistent, valvular) undergoing AF ablation for clinical
      indication. Both endocardial and body surface mapping results will be correlated with
      biomarkers levels, MRI scans and AF outcomes of AF ablation at 6 months and 1 year after the
      procedure.

      Wide antrum circumferential pulmonary vein isolation with demonstration of bidirectional
      block will be performed using standard cooled-tip radiofrequency catheters. In patients with
      mitral stenosis, PBMV will be performed according to Inoue´s technique followed by wide
      antrum circumferential pulmonary vein isolation. In all patients, MRI/CT scans and fibrosis
      biomarkers will be obtained at baseline, 6 months and 1 year post ablation.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>February 2015</start_date>
  <completion_date type="Anticipated">June 2017</completion_date>
  <primary_completion_date type="Anticipated">June 2016</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Freedom from atrial fibrillation off antiarrhythmic medications in patients with either paroxysmal, persistent AF or valvular stenosis AF.</measure>
    <time_frame>12 months post-first ablation procedure</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Freedom from atrial fibrillation on or off antiarrhythmic medication post-first ablation procedure and after redo procedures.</measure>
    <time_frame>at 6 and 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Freedom from atrial fibrillation and other atrial arrhythmias post-first ablation procedure and after redo procedures.</measure>
    <time_frame>at 6 and 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of peri-procedural complications</measure>
    <time_frame>during ablation procedure and 12 months after</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Procedure duration</measure>
    <time_frame>Duration of ablation procedure, and valvuloplasty if indicated, in minutes</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Body surface recording analysis by 120 disposable electrodes distributed over the patient's chest and connected to the polygraph.</measure>
    <time_frame>During ablation procedure, and valvuloplasty if indicated</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Electroanatomic reconstruction and recordings of electrical activity: a three-dimensional reconstruction of atrium and coronary sinus is obtained using high density catheters and an electroanatomic navigation system.</measure>
    <time_frame>During ablation procedure, and valvuloplasty if indicated</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Atrial fibrosis determination using late gadolinium enhancement-MRI</measure>
    <time_frame>At 6 and 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fluoroscopy time</measure>
    <time_frame>During ablation procedure, and valvuloplasty if indicated, in minutes</time_frame>
  </secondary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Atrial Fibrillation</condition>
  <arm_group>
    <arm_group_label>- Patients with paroxysmal AF.</arm_group_label>
    <description>Patients with AF episodes that terminates spontaneously or with intervention in less than seven days with clinical indication of pulmonary vein ablation.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>- Patients with persistent AF.</arm_group_label>
    <description>Patients with AF episodes that fails to self-terminate within seven days or require pharmacologic or electrical cardioversion to restore sinus rhythm with clinical indication of pulmonary vein ablation..</description>
  </arm_group>
  <arm_group>
    <arm_group_label>- Patients with mitral stenosis.</arm_group_label>
    <description>- Patients with mitral stenosis and clinical indication for AF ablation undergoing percutaneous balloon mitral valvuloplasty (PBMV) with clinical indication of pulmonary vein ablation..</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Pulmonary vein ablation</intervention_name>
    <description>Simultaneous biatrial endocardial electroanatomical mapping by high-density basket catheter (64 pin) and customized body surface mapping (57 electrodes) followed by circumferential pulmonary vein ablation.</description>
    <arm_group_label>- Patients with paroxysmal AF.</arm_group_label>
    <arm_group_label>- Patients with persistent AF.</arm_group_label>
    <arm_group_label>- Patients with mitral stenosis.</arm_group_label>
    <other_name>Mitral Valvuloplasty in patients with severe mitral stenosis</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        AF patients with different mechanisms of maintenance (i.e. paroxysmal, persistent,
        valvular) and clinical indication for AF ablation.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with paroxysmal AF symptomatic and refractory to at least one antiarrhythmic
             medication.

          -  Patients with persistent AF symptomatic and refractory to at least one antiarrhythmic
             medication.

          -  Patients with severe mitral stenosis (mitral valve area ≤1.5 cm2, stage D) and
             favorable valve morphology in the absence of left atrial thrombus or
             moderate-to-severe mitral regurgitation.

          -  Patients must be able and willing to provide written informed consent to participate
             in the study.

          -  Prior anticoagulation for&gt; 4 weeks or transesophageal echocardiogram excluding
             intracardiac thrombi (in patients with paroxysmal AF).

        Exclusion Criteria:

          -  Patients with inadequate anticoagulation levels.

          -  Patients with left atrial thrombus, tumor, or another abnormality which precludes
             catheter introduction on TEE prior to the procedure.

          -  Patients with moderate-to-severe mitral regurgitation.

          -  Patients with contraindications to systemic anticoagulation with heparin or coumadin.

          -  Prior atrial fibrillation ablation.

          -  Patients who are or may potentially be pregnant.

          -  Contraindication for adenosine administration;

          -  Current enrollment in another investigational drug or device study.

          -  Pacemaker or Implantable Cardioverter Defibrillator.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Felipe Atienza, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Red de Investigación Cardiovascular</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Felipe Atienza, MD</last_name>
    <phone>+00 34 91 586 82 86</phone>
    <email>felipe.atienza@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Lourdes Vicent, MD</last_name>
    <phone>+00 34 91 586 82 86</phone>
    <email>mlourdesvicent@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Felipe Atienza Fernandez</name>
      <address>
        <city>Madrid</city>
        <zip>28007</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Felipe Atienza, MD</last_name>
      <phone>+00 34 91 586 82 86</phone>
      <email>felipe.atienza@gmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Lourdes Vicent, MD</last_name>
      <email>mlourdesvicent@gmail.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <reference>
    <citation>Atienza F, Almendral J, Ormaetxe JM, Moya A, Martínez-Alday JD, Hernández-Madrid A, Castellanos E, Arribas F, Arias MÁ, Tercedor L, Peinado R, Arcocha MF, Ortiz M, Martínez-Alzamora N, Arenal A, Fernández-Avilés F, Jalife J; RADAR-AF Investigators. Comparison of radiofrequency catheter ablation of drivers and circumferential pulmonary vein isolation in atrial fibrillation: a noninferiority randomized multicenter RADAR-AF trial. J Am Coll Cardiol. 2014 Dec 16;64(23):2455-67. doi: 10.1016/j.jacc.2014.09.053.</citation>
    <PMID>25500229</PMID>
  </reference>
  <verification_date>July 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 30, 2015</study_first_submitted>
  <study_first_submitted_qc>July 10, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 14, 2015</study_first_posted>
  <last_update_submitted>July 10, 2015</last_update_submitted>
  <last_update_submitted_qc>July 10, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 14, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Atrial Fibrillation</keyword>
  <keyword>Pulmonary Vein Ablation</keyword>
  <keyword>Mitral stenosis</keyword>
  <keyword>Body surface mapping</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atrial Fibrillation</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

